Copyright © 2006, European Society of Cardiology
Activin-like kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells
aDivision of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, United States
bMolecular Biology Institute, UCLA, Los Angeles, CA 90095-1570, United States
* Corresponding author. Division of Cardiology, David Geffen School of Medicine at UCLA, Box 951679, Room BH-307 CHS, Los Angeles, CA 90095-1679, United States. Tel.: +1 310 794 4417; fax: +1 310 206 8553. Email address: kbostrom{at}mednet.ucla.edu
Objective: Activin-like kinase receptor 1 (ALK1) is a transforming growth factor (TGF)-β type I receptor expressed in vascular mesenchyme, yet its function in vascular mesenchymal cells (VMC) is unclear. We examined ALK1 expression in human coronary atherosclerotic lesions and bovine and human VMC undergoing cellular condensation in vitro. We also examined the effect of activated ALK1 on cell proliferation and smooth muscle cell (SMC) differentiation.
Methods and results: Our results showed that ALK1 was expressed in human coronary atherosclerotic lesions as determined by immunohistochemistry. ALK1 was also expressed in cellular condensations of bovine and human VMC as determined by real-time PCR and immunocytochemistry. Bone morphogenetic protein (BMP)-2, which is known to increase condensation size, increased ALK1 expression when induced from a BMP-2 adenoviral vector. In turn, activated ALK1 induced expression of matrix GLA protein (MGP), a BMP-2 inhibitor known to limit condensation size. Activated ALK1 enhanced proliferation of VMC as determined by 3H-thymidine incorporation, whereas MGP decreased proliferation. Activated ALK1 also enhanced expression of SMC lineage markers and ALK5, another TGF-β type I receptor, as determined by immunoblotting, real-time PCR and immunocytochemistry. Anti-TGF-β antibodies abolished expression of SMC markers in the presence of constitutively active ALK1, suggesting that ALK1 activation alone is not sufficient to promote SMC differentiation.
Conclusions: We conclude that there is a balance between the actions of BMP-2 and MGP in the initiation of vascular mesenchymal cell condensation and SMC differentiation, and that targeting ALK1, BMP2 and/or MGP may lead to novel concepts of atherosclerosis treatment.
KEYWORDS Activin-like kinase receptor 1; Bone morphogenetic protein; Matrix GLA protein; Vascular mesenchymal cells; Smooth muscle cell differentiation
Time for primary review 39 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Yao, E. S. Shao, M. Jumabay, A. Shahbazian, S. Ji, and K. I. Bostrom High-Density Lipoproteins Affect Endothelial BMP-Signaling by Modulating Expression of the Activin-Like Kinase Receptor 1 and 2 Arterioscler. Thromb. Vasc. Biol., December 1, 2008; 28(12): 2266 - 2274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Li, W. Yin, X. Hong, Y. Shi, H.-S. Wang, S.-F. Lin, and S.-B. Tang Remodeling Retinal Neovascularization by ALK1 Gene Transfection In Vitro Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4553 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yao, A. Shahbazian, and K. I. Bostrom Proline and {gamma}-Carboxylated Glutamate Residues in Matrix Gla Protein Are Critical for Binding of Bone Morphogenetic Protein-4 Circ. Res., May 9, 2008; 102(9): 1065 - 1074. [Abstract] [Full Text] [PDF]
|
|